In the pursuit of effective interventions against the relentless progression of Alzheimer’s disease (AD), recent research has witnessed a paradigm shift towards targeted therapeutic approaches. This comprehensive review critically examines the latest advancements in AD treatment modalities, focusing on the burgeoning field of targeted therapy. Drawing insights from a plethora of preclinical studies, clinical trials, and experimental models, the review sheds light on novel therapeutic targets and innovative strategies aimed at halting the pathological cascade of AD. Notably, advancements in understanding the intricate molecular mechanisms underlying AD pathology have paved the way for the development of precision-targeted interventions.
The review elucidates the multifaceted nature of AD pathogenesis, emphasizing the role of amyloid-beta oligomers, tau protein aggregation, and neuroinflammation as key pathological hallmarks. Leveraging this intricate understanding, researchers have endeavored to devise a spectrum of targeted therapeutic approaches, ranging from monoclonal antibody therapies to small molecule inhibitors and gene-based interventions. Promising findings from preclinical studies have propelled several candidate drugs into clinical trials, offering new hope for disease modification and symptomatic relief in AD patients. However, challenges such as treatment efficacy, safety profiles, and the complexity of disease heterogeneity persist, underscoring the need for continued research efforts and interdisciplinary collaboration to unlock the full therapeutic potential of targeted therapy in combating AD.
